Seeking global deals, Taiho swells its U.S.-based VC fund to $300M

Dollar arrow pointing up
While still focused primarily on cancer, Taiho Ventures may look at opportunities in other areas. (ImagePixel/iStock/Getty Images Plus)

Seeking further returns from Taiho Ventures, Taiho Pharma just decided to multiply the VC’s investment pool sixfold to $300 million, adding to the already-plentiful supply of cash for early-stage biotechs.

California-based Taiho Ventures was set up with a $50 million fund in 2016 with the aim of backing biotech startups involved in leading-edge cancer research that could develop into pipeline-boosting strategic alliances. Two years on—with a portfolio that includes Arcus Biosciences, PACT Pharma, Harpoon Therapeutics, Storm Therapeutics, ORIC Pharmaceuticals and Quentis Therapeutics—the fund is looking to extend its reach and, while still focused primarily on cancer, may look at opportunities in other areas.

The investments made to date have already started to add to Taiho Pharma’s pipeline, but the drugmaker says it wants to step up its pursuit of international deals that will help it meet its goal of becoming a “global” oncology company. So far, its efforts have resulted most notably in a $130 million licensing deal—agreed on in July—for Japanese and certain other Asian rights to AB928, billed as a first-in-class dual adenosine receptor antagonist in development as a cancer immunotherapy.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

AB928 is an oral small molecule that inhibits adenosine 2a and 2b receptors, which are thought to be involved in suppressing immune responses in the tumor microenvironment. It is currently in early-stage clinical development for triple-negative breast cancer and ovarian cancer, in combination with Arcus’ anti-PD-1 antibody AB122 and with chemotherapy.

Taiho Pharma President Masayuki Kobayashi said that while in-house drug discovery at its facilities in Japan will continue to be the “mainstay” of its R&D, the company “will also continue to access groundbreaking innovation, primarily in the oncology field, through Taiho Ventures, in an effort to further strengthen its drug discovery capabilities.”

Suggested Articles

Trials for cancer drugs undertaken in Europe in the mid-2010s were flawed to such a degree as to “raise questions” over their true benefits to patients.

About 10 months after first announcing the move, Google has finally subsumed the healthcare-focused efforts of DeepMind.

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.